In Brief

Vitamin Shoppe buys Super Supplements; investor Ackman wages war on Herbalife; NPA cancels MarketPlace show; Herbalife acquires N.C. facility; Capsugel expands quality control; AHP releases aloe vera monograph standard: more news In Brief.

[Vitamin Shoppe Inc.] expands its foothold in the Pacific Northwest U.S. with the acquisition of Seattle-based Super Supplements Inc. for $50 million, the North Bergen, N.J., based firm announced Dec. 17. The deal, which is expected to close Dec. 31 pending customary closing conditions, adds 31 stores to Vitamin Shoppe’s existing 17 stores in Washington, Oregon and Idaho. Vitamin Shoppe expects the deal will contribute $75 million in revenue in 2013 and a neutral or slightly positive impact on earnings per share.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Ryoncil Chronology: Three Review Cycles, Two CRLs, One Dispute Resolution Request

 
• By 

The Pink Sheet’s Drug Review Profile looks at the timeline for the clinical development and US FDA review of Mesoblast’s remestemcel for graft-versus-host disease.

Pink Sheet Podcast: More US FDA Departures, Makary On Combined AE Database, ‘Conditional’ Approval

 

Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.

Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval

 

The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.